urgent
need
rapid
method
develop
vaccin
respons
emerg
viral
pathogen
whole
inactiv
viru
wiv
vaccin
repres
ideal
strategi
purpos
howev
univers
method
produc
safe
immunogen
inactiv
vaccin
lack
convent
pathogen
inactiv
method
formalin
heat
ultraviolet
light
gamma
ray
caus
structur
alter
vaccin
lead
reduc
neutral
antibodi
specif
case
disastr
helper
type
immun
patholog
evalu
potenti
visibl
ultrashort
puls
usp
laser
method
gener
safe
immunogen
wiv
vaccin
without
adjuv
specif
demonstr
vaccin
mice
laserinactiv
influenza
viru
lower
dose
requir
use
convent
formalininactiv
influenza
vaccin
result
protect
lethal
challeng
mice
viru
inactiv
usp
laser
irradi
shown
retain
surfac
protein
structur
hemagglutin
assay
unlik
convent
inactiv
method
laser
treatment
gener
carbonyl
group
protein
therebi
reduc
risk
advers
vaccineelicit
helper
type
respons
therefor
usp
laser
treatment
attract
potenti
strategi
gener
wiv
vaccin
greater
potenc
safeti
vaccin
produc
current
inactiv
techniqu
emerg
viral
pathogen
constant
promin
threat
human
health
worldwid
evidenc
recent
outbreak
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
coronavirus
novel
influenza
strain
pandem
potenti
addit
persist
risk
engin
virus
deriv
bioterror
logic
costeffect
strategi
protect
human
popul
emerg
viral
diseas
immun
thu
dire
need
rapid
method
develop
vaccin
respons
new
viral
pathogen
whole
inactiv
viru
wiv
vaccin
repres
ideal
strategi
purpos
contrast
subunit
recombin
vector
vaccin
wiv
vaccin
circumv
need
identifi
relev
antigen
quickli
produc
purifi
viru
use
chemic
physic
inactiv
method
wiv
vaccin
contain
mani
immunogen
epitop
immunostimulatori
compon
tolllik
receptor
ligand
need
effect
virusspecif
immun
respons
unfortun
gener
method
produc
safe
immunogen
wiv
vaccin
lack
formalin
alkyl
agent
one
extens
use
method
viru
inactiv
manufactur
vaccin
howev
formalin
treatment
sever
crucial
limit
caus
structur
damag
bcell
epitop
reduc
specif
antibodi
respons
elicit
vaccin
gener
carbonyl
group
protein
form
oxid
damag
induc
harm
undesir
helper
type
bias
immun
respons
add
unnecessari
cost
public
concern
introduc
carcinogen
vaccin
limit
seen
failur
formalininactiv
respiratori
syncyti
viru
measl
vaccin
caus
disastr
worsen
diseas
upon
natur
infect
altern
method
viru
inactiv
includ
alkyl
agent
heat
ultraviolet
uv
light
gamma
radiat
suffer
variou
combin
abovement
limit
recent
novel
method
pathogen
inactiv
use
visibl
ultrashort
puls
usp
laser
report
ref
visibl
usp
laser
treatment
inactiv
virus
physic
mechan
impuls
stimul
raman
scatter
isr
process
sever
theoret
reason
usp
laser
would
advantag
method
wiv
vaccin
product
visibl
light
wavelength
rang
nm
lack
photon
energi
disrupt
coval
bond
biolog
macromolecul
virus
therefor
usp
laser
irradi
gener
responseinduc
carbonyl
group
protein
absenc
chromophor
visibl
light
show
neglig
intrins
absorpt
protein
nucleic
acid
thu
usp
laser
irradi
denatur
structur
bcell
epitop
heat
addit
usp
laser
irradi
induc
proteinnucl
acid
crosslink
henc
tlrstimul
capac
viral
nucleic
acid
preserv
furthermor
usp
laser
method
involv
introduc
potenti
toxic
carcinogen
chemic
treatment
would
allevi
public
concern
regard
rational
make
usp
laser
treatment
attract
potenti
method
gener
safe
effect
wiv
vaccin
paper
demonstr
immun
mice
usp
laserinactiv
whole
inactiv
influenza
viru
lower
dose
requir
convent
formalininactiv
vaccin
result
protect
lethaldos
influenza
challeng
splenocyt
extract
mice
vaccin
usp
laserinactiv
viru
show
enhanc
influenzaspecif
cytotox
tcell
ctl
respons
compar
unvaccin
mice
addit
employ
neutral
assay
confirm
presenc
neutral
antibodi
demonstr
hemagglutin
assay
usp
laser
irradi
effect
surfac
protein
structur
viru
furthermor
evalu
effect
usp
lasertreat
model
proteinbovin
serum
albumin
bsa
found
contrast
convent
pathogen
inactiv
method
usp
laser
treatment
gener
responseinduc
carbonyl
group
bsa
protein
therefor
usp
laser
treatment
novel
attract
potenti
strategi
gener
wiv
vaccin
greater
potenc
safeti
vaccin
produc
current
inactiv
techniqu
femal
balbc
mice
week
old
obtain
nation
cancer
institut
bethesda
maryland
mice
kept
pathogenfre
environ
john
hopkin
univers
baltimor
maryland
madindarbi
canin
kidney
mdck
cell
obtain
atcc
manassa
virginia
use
vitro
assay
cell
grown
dulbecco
modifi
eagl
medium
dmem
lglutamin
fb
co
strain
viru
use
studi
atcc
manassa
virginia
viru
first
grown
mdck
host
cell
centrifug
g
min
cell
debri
remov
remain
viru
particl
concentr
centrifug
g
h
sucros
cushion
phosphat
buffer
salin
pb
viru
store
aliquot
titer
viru
measur
tissu
cultur
infecti
tcid
assay
tcid
assay
mdck
cell
plate
plate
viru
ad
dilut
use
infect
media
dmem
nacetyl
trypsin
bsa
success
row
well
plate
store
incub
co
day
formaldehyd
ad
fix
cell
naphthol
blueblack
ad
stain
fix
cell
plate
wash
infecti
dose
calcul
use
reedmuench
method
excit
laser
sourc
employ
work
diodepump
modelock
tisapphir
laser
laser
produc
continu
train
fs
puls
repetit
rate
mhz
output
secondharmon
gener
tisapphir
laser
use
irradi
sampl
excit
laser
chosen
oper
wavelength
nm
averag
power
mw
puls
width
full
width
half
maximum
fs
achromat
len
focu
length
cm
use
focu
laser
beam
sampl
area
order
facilit
interact
laser
influenza
viru
particl
place
insid
pyrex
cuvett
buffer
solut
magnet
stirrer
set
virion
would
enter
laserfocus
volum
laserirradi
influenza
sampl
contain
approxim
tcid
viru
volum
typic
exposur
time
sampl
laser
irradi
h
diamet
laser
beam
approxim
within
cuvett
effect
laser
exposur
time
individu
virion
estim
steril
influenza
viru
sampl
laser
treatment
confirm
tcid
assay
experiment
result
report
obtain
singl
laser
beam
excit
temperatur
increas
sampl
solut
usp
laser
treatment
monitor
thermocoupl
exceed
inactiv
viru
store
aliquot
use
subsequ
vaccin
experi
live
usp
laserinactiv
viru
prepar
serial
twofolddilut
ml
volum
microtitr
plate
chicken
erythrocyt
suspens
ad
well
plate
incub
min
ice
hemagglutin
assay
adapt
current
protocol
microbiolog
group
mice
vaccin
twice
interv
previous
describ
tcid
laserinactiv
viru
intranas
administr
control
mice
receiv
vaccin
mice
group
maintain
consist
weight
prior
administr
challeng
dose
two
week
last
vaccin
mice
challeng
lethal
dose
tcid
weight
mice
daili
monitor
mice
lose
bodi
weight
consid
reach
experiment
endpoint
euthan
two
week
last
vaccin
mice
sacrif
splenocyt
isol
stimul
use
influenza
nucleoprotein
peptid
np
detect
cellular
surfac
intracellular
perform
use
flow
cytometri
previous
describ
briefli
cell
incub
overnight
golgiplug
bd
pharmingen
presenc
np
peptid
wash
facscan
buffer
cell
stain
phycoerythrinconjug
antimous
antibodi
cell
incub
bd
cytofixcytoperm
solut
bd
pharmingen
follow
stain
fitcconjug
antimous
antibodi
splenocyt
mice
group
pool
togeth
analyz
flow
cytometri
bectondickinson
facscalibur
cellquest
softwar
bd
bioscienc
mountain
view
california
gate
perform
lymphocyt
area
blood
collect
tail
vein
vaccin
n
unvaccin
n
mice
week
last
vaccin
serum
store
aliquot
serum
collect
mice
test
neutral
antibodi
follow
mdck
cell
plate
well
plate
serum
dilut
infect
media
dmem
nacetyl
trypsin
bsa
ad
first
row
well
contain
mdck
cell
thorough
mix
well
content
first
row
well
ad
infect
media
next
row
procedur
continu
last
row
well
result
twofold
dilut
extra
serum
discard
constant
concentr
tcid
use
plate
viru
serum
incub
hour
ad
plate
mdck
cell
plate
store
three
night
incub
co
formaldehyd
naphthol
blueblack
ad
visual
result
reaction
tcid
assay
assay
repeat
three
time
neutral
titer
calcul
use
reedmuench
method
invers
highest
dilut
protect
achiev
determin
neutral
titer
serum
level
antiinfluenza
antibodi
sera
determin
direct
enzymelink
immunosorb
assay
elisa
previous
describ
briefli
well
plate
coat
influenza
incub
overnight
well
block
pb
contain
fetal
bovin
serum
sera
prepar
mice
day
postimmun
time
dilut
pb
ad
elisa
well
incub
h
wash
pb
contain
tween
plate
incub
dilut
peroxidaseconjug
rabbit
antimous
immunoglobulin
g
antibodi
zyme
san
francisco
california
room
temperatur
h
plate
wash
six
time
turbo
tmbelisa
use
substrat
color
develop
pierc
rockford
illinoi
color
develop
stop
h
absorb
elisa
plate
well
determin
standard
elisa
reader
nm
carbonyl
concentr
untreat
bsa
usp
lasertr
bsa
uvtreat
bsa
assess
use
dinitrophenylhydrazin
dnph
base
protein
carbonyl
colorimetr
assay
kit
cayman
chemic
accord
manufactur
instruct
uv
treatment
group
bsa
sampl
expos
phillip
germicid
uvc
lamp
distanc
bulb
min
data
analyz
use
microsoft
excel
experi
repeat
duplic
triplic
individu
data
point
compar
use
student
test
hemagglutin
activ
usp
laser
viru
inactiv
provid
one
indic
structur
altern
surfac
protein
viru
inactiv
treatment
purifi
influenza
stock
aliquot
batch
treat
usp
laser
irradi
follow
complet
loss
infect
compar
hemagglutin
activ
live
inactiv
virus
shown
tabl
within
experiment
uncertainti
hemagglutin
activ
affect
usp
laser
irradi
result
provid
evid
usp
laser
irradi
among
inactiv
method
caus
least
structur
chang
viral
surfac
protein
determin
whether
laserinactiv
viru
vaccin
confer
protect
lethal
dose
percent
chang
initi
weight
use
indic
health
mice
group
mice
receiv
vaccin
n
treatment
n
two
week
last
vaccin
mice
group
given
lethal
dose
tcid
live
viru
follow
administr
challeng
dose
weight
mice
control
group
rapidli
decreas
shown
fig
seventh
day
receiv
challeng
dose
control
mice
lost
signific
percentag
initi
weight
mice
vaccin
group
maintain
healthi
weight
result
show
vaccin
effect
challeng
lethal
dose
investig
immun
gener
vaccin
laserinactiv
viru
ctl
activ
assess
splenocyt
obtain
vaccin
untreat
mice
stimul
immunogen
influenza
np
peptid
cell
fluoresc
tag
analyz
flow
cytometri
figur
demonstr
vaccin
mice
show
increas
percentag
activ
np
peptidespecif
cell
comparison
control
mice
data
indic
vaccin
laserinactiv
viru
gener
influenza
antigenspecif
cell
immun
respons
next
investig
humor
immun
induc
vaccin
use
microneutr
assay
neutral
assay
sensit
specif
techniqu
measur
neutral
antibodi
respons
viru
shown
fig
found
sera
mice
receiv
laserinactiv
vaccin
show
significantli
higher
neutral
antibodi
titer
compar
sera
control
unvaccin
mice
furthermor
observ
vaccin
decreas
dose
laserinactiv
influenza
viru
gener
virusspecif
antibodi
respons
lesser
degre
experiment
result
indic
vaccin
laserinactiv
viru
induc
neutral
antibodi
immun
respons
use
transmiss
electron
microscopi
tem
visual
examin
activ
laserinactiv
influenza
virus
figur
b
show
tem
imag
influenza
viru
without
laser
irradi
respect
found
global
structur
viru
maintain
usp
laser
treatment
indic
product
wiv
usp
laser
irradi
convent
inactiv
method
includ
formalin
uv
treatment
gamma
radiat
potent
induc
carbonyl
group
protein
carbonyl
group
turn
induc
harm
undesir
helper
type
respons
determin
whether
laser
treatment
gener
protein
carbonyl
use
colorimetr
dnph
base
assay
quantit
carbonyl
content
lasertr
bsa
untreat
bsa
uvtreat
bsa
serv
neg
posit
control
respect
figur
show
signific
increas
carbonyl
content
lasertr
bsa
sampl
rel
untreat
bsa
contrast
carbonyl
content
uvtreat
bsa
dramat
increas
rel
untreat
lasertr
bsa
p
result
demonstr
usp
laser
treatment
gener
fewer
carbonyl
group
protein
antigen
compar
convent
pathogen
inactiv
method
reduc
risk
detriment
vaccineelicit
respons
follow
two
reason
complet
inactiv
flu
virus
sampl
usp
laser
irradi
observ
experi
use
vaccin
due
twophoton
absorpt
effect
first
estim
number
uvc
photon
might
produc
laser
power
densiti
use
experi
twophoton
absorpt
coeffici
flu
viru
avail
literatur
howev
assum
virus
giant
molecul
twophoton
absorpt
coeffici
nm
compar
typic
molecul
number
uvc
photon
nm
gener
experiment
condit
estim
order
second
laser
exposur
time
h
number
gener
uvc
photon
total
laser
exposur
time
hand
total
number
viral
particl
laserirradi
sampl
million
sinc
one
uvc
photon
nm
inactiv
one
viral
particl
valu
gener
uvc
photon
total
laser
exposur
time
small
account
complet
inactiv
million
viral
particl
observ
experi
second
tri
detect
uvc
photon
might
gener
laser
experi
glass
vial
replac
synthet
fuse
silica
vial
use
uv
spectromet
photon
count
system
within
experiment
uncertainti
fail
detect
uvc
photon
nm
find
consist
estim
state
addit
note
absorpt
coeffici
water
nm
cm
mean
effect
water
absorpt
nm
neglig
reason
detect
uvc
photon
therefor
observ
complet
inactiv
flu
viru
observ
experi
due
uvc
photon
gener
twophoton
absorpt
shown
nonenvelop
virus
murin
noroviru
mnv
inactiv
visibl
usp
laser
isr
process
wherebi
usp
laser
puls
excit
ramanact
vibrat
mode
capsid
nonenvelop
fig
neutral
antibodi
detect
microneutr
assay
serum
vaccin
n
unvaccin
n
group
mice
extract
day
vaccin
ad
madindarbi
canin
kidney
mdck
cell
plate
serial
dilut
incub
day
subsequ
constant
concentr
tcid
use
plate
viru
serum
incub
h
ad
plate
mdck
cell
plate
store
three
night
incub
co
formaldehyd
naphthol
blueblack
ad
visual
result
reaction
presenc
neutral
antibodi
determin
cell
surviv
neutral
titer
calcul
use
reedmuench
method
bar
graph
depict
neutral
titer
untreat
vaccin
mice
p
viru
mnv
amplitud
vibrat
linearli
proport
laser
intens
laser
intens
suffici
larg
excit
amplitud
vibrat
capsid
becom
extrem
larg
lead
break
weak
link
hydrogen
bond
hydrophob
contact
capsid
viru
caus
capsid
disintegr
subunit
viru
becom
inactiv
loss
integr
capsid
hand
demonstr
envelop
virus
murin
cytomegaloviru
mcmv
inactiv
visibl
usp
laser
via
isr
process
well
differ
routepathway
usp
laser
puls
excit
ramanact
mode
protein
capsid
well
tegument
protein
envelop
viru
mcmv
impuls
stimul
raman
scatter
process
excit
break
hydrogen
bond
hydrophob
contact
protein
caus
partial
unfold
protein
unfold
protein
rapidli
reform
broken
weak
hydrogen
bond
hydrophob
contact
return
origin
fold
configur
howev
concentr
protein
high
case
protein
confin
within
capsid
viru
form
hydrogen
bond
hydrophob
contact
protein
nearbi
lead
aggreg
protein
case
envelop
viru
mcmv
aggreg
capsid
protein
tegument
protein
found
caus
inactiv
envelop
viru
influenza
virus
envelop
virus
therefor
believ
like
inactiv
mechan
influenza
viru
inactiv
visibl
usp
laser
studi
isr
process
tem
imag
influenza
viru
usp
laser
irradi
shown
fig
support
argument
strike
similar
tem
imag
mcmv
ie
retent
capsid
global
structur
viru
suggest
effect
therefor
underlin
inactiv
mechan
usp
laser
irradi
two
envelop
virus
give
perspect
vaccin
potenc
report
current
studi
illustr
compar
vaccin
dosag
requir
protect
lethal
challeng
mice
use
convent
laserinactiv
influenza
vaccin
among
convent
method
includ
heat
formalin
beta
propiolacton
deterg
formalin
found
greatest
preserv
influenza
vaccin
antigen
perform
addit
experi
two
control
group
mice
got
convent
formalininactiv
influenza
vaccin
figur
show
one
control
group
vaccin
two
dose
convent
formalininactiv
vaccin
dose
usp
laserinactiv
vaccin
use
protect
challeng
figur
b
show
control
group
vaccin
two
dose
convent
formalininactiv
vaccin
mice
control
group
fig
die
weight
decreas
initi
one
day
challeng
wherea
mice
control
group
fig
b
achiev
protect
hand
visibl
usp
laser
irradi
method
employ
two
dose
usp
laserinactiv
vaccin
lower
dose
rel
formalininactiv
vaccin
achiev
protect
therefor
result
indic
usp
laserinactiv
vaccin
significantli
effici
vaccin
prepar
convent
formalininactiv
vaccin
rel
high
potenc
usp
laserinactiv
influenza
viru
vaccin
partli
attribut
fact
visibl
usp
laser
irradi
minim
effect
structur
protein
circular
dichroism
cd
spectrum
bsa
protein
measur
usp
laser
irradi
good
exampl
cd
spectrum
sensit
secondari
structur
protein
shown
within
experiment
uncertainti
chang
cd
spectrum
bsa
protein
usp
laser
irradi
spectroscop
result
line
hemagglutin
activ
result
experiment
result
hemagglutin
activ
viru
show
within
experiment
uncertainti
usp
laser
irradi
effect
surfac
protein
structur
viru
note
usp
laserinactiv
influenza
vaccin
may
gener
heterosubtyp
immun
aim
current
effort
design
univers
influenza
vaccin
ctl
respons
key
mechan
improv
heterosubtyp
protect
influenza
ctl
shown
specif
epitop
conserv
among
viral
subtyp
data
show
splenocyt
vaccin
mice
show
increas
influenza
npspecif
ctl
compar
unvaccin
mice
result
suggest
laserinactiv
influenza
vaccin
potenti
gener
crossprotect
multipl
strain
address
issu
viral
mutat
presenc
carbonyl
group
vaccin
antigen
link
induct
undesir
potenti
deleteri
immunopatholog
mani
inactiv
techniqu
includ
uv
gamma
radiat
potent
induc
protein
carbonyl
note
although
formaldehyd
oxid
agent
produc
oxid
damag
cell
free
system
carbonyl
group
introduc
protein
formaldehyd
formalin
inactiv
techniqu
someth
common
carbonyl
group
introduc
protein
oxid
contrast
techniqu
visibl
usp
laser
lack
energi
disrupt
coval
structur
protein
therefor
reason
usp
laser
treatment
would
caus
protein
carbonyl
experiment
result
fig
confirm
data
demonstr
usp
laser
treatment
gener
signific
level
carbonyl
group
protein
antigen
compar
convent
pathogen
inactiv
method
reduc
risk
detriment
vaccineelicit
respons
addit
carbonyl
group
type
coval
damag
caus
formalin
uv
gamma
radiat
result
format
neoantigen
elicit
advers
immun
reaction
administ
patient
seen
penicillin
allergi
certain
chemic
treat
blood
product
contrast
usp
laser
inactiv
envelop
influenza
viru
disrupt
weak
noncoval
hydrogen
bond
hydrophob
contact
virion
lead
aggreg
capsid
tegument
protein
result
overal
reduc
concern
side
effect
vaccin
prepar
usp
laser
treatment
method
summari
demonstr
novel
usp
laser
irradi
method
product
safe
potent
wiv
vaccin
envis
futur
pathogen
inactiv
technolog
favor
chemicalfre
method
target
properti
specif
pathogen
preserv
desir
compon
treat
product
lead
improv
safeti
profil
usp
laser
irradi
method
present
report
one
potenti
technolog
evalu
usp
laserinactiv
vaccin
crossprotect
context
import
pathogen
hiv
sar
mer
warrant
